Enzyme-cleavable prodrug compounds

Details Enzyme-cleavable prodrug compounds Enzyme-cleavable prodrug compounds

2001-06-11

2008-09-16

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000, C530S333000, C530S345000

Reexamination Certificate

active

07425541

ABSTRACT:
The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.

REFERENCES:
patent: 4144333 (1979-03-01), Hall et al.
patent: 4277466 (1981-07-01), Trouet et al.
patent: 4296105 (1981-10-01), Baurain et al.
patent: 4376765 (1983-03-01), Trouet et al.
patent: 4388305 (1983-06-01), Trouet et al.
patent: 4639456 (1987-01-01), Trouet et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 4719312 (1988-01-01), Firestone
patent: 4870162 (1989-09-01), Trouet et al.
patent: 4931544 (1990-06-01), Katre et al.
patent: 5024835 (1991-06-01), Rao et al.
patent: 5220001 (1993-06-01), Ok et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5574017 (1996-11-01), Gutheil
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5833986 (1998-11-01), LaRochelle et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5962216 (1999-10-01), Trouet et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6265540 (2001-07-01), Isaacs et al.
patent: 6372712 (2002-04-01), Briesewitz et al.
patent: 6680054 (2004-01-01), Reece et al.
patent: 6897034 (2005-05-01), Bebbington et al.
patent: 6989452 (2006-01-01), Ng et al.
patent: 7087600 (2006-08-01), Ng et al.
patent: 7115573 (2006-10-01), Pickford et al.
patent: 7129261 (2006-10-01), Ng et al.
patent: 7214663 (2007-05-01), Bebbington et al.
patent: 2003/0119021 (2003-06-01), Koster et al.
patent: 2004/0039160 (2004-02-01), Pickford et al.
patent: 869 485 (1978-12-01), None
patent: 882 541 (1980-07-01), None
patent: 0 037 388 (1981-03-01), None
patent: 0 041 935 (1981-12-01), None
patent: 0 044 090 (1982-01-01), None
patent: 0 126 685 (1984-11-01), None
patent: 0 208 615 (1987-01-01), None
patent: 0 475 230 (1991-09-01), None
patent: 0 640 622 (1994-02-01), None
patent: 0 126 344 (1994-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 92/07068 (1992-04-01), None
patent: WO 93/02703 (1993-02-01), None
patent: WO 96/00503 (1996-01-01), None
patent: WO 96/05863 (1996-02-01), None
patent: WO 96/33198 (1996-10-01), None
patent: WO 9821243 (1998-05-01), None
patent: WO 98/52966 (1998-11-01), None
patent: WO 00/33888 (2000-06-01), None
CH Li and L Bertsch. J. Biol. Chem. (1960) 235, 2638-2641.
C Pan, et al. Cancer Research. (2003) 63, 5526-5531.
DC DeJongh, et al. Biomed. Mass Spec. (1976) 3, 191-195.
U Beyer, et al. J. Med. Chem. (1998) 41, 2701-2708.
T Kaneko, et al. Bioconjugate Chemistry. (1991) 2, 133-141.
F Kratz, et al. Arch. Pharm. Pharm. Med. Chem. (1998) 331, 47-53.
H.F. Gaertner and R.E. Offord. Bioconj. Chem. (1996) 7(1), pp. 38-44.
Y. Inada, et al. Methods Enzymol. (1994) 242, pp. 65-90.
J.S. Holcenberg, et al. J. Biol. Chem. (1975) 250(11), pp. 4165-4170.
R.S. Kania et al. J. Am. Chem. Soc. (1994) 116(19), pp. 8835-8836.
Abold-Pirak, Esther, et al., “Cytotoxic activity of Daunorubicin or Vindesin Conjugated to a Monoclonal Antibody on Cultured MCF-7 Breast Carcinoma Cells,”Biochem. Pharmacol.38:641-648 (1989).
Balajthy et al., “Synthesis and Functional Evaluation of a Peptide Derivative of 1-β-D-Arabinofuranosylcytosine,”J. Med. Chem.35:3344-3349 (1992).
Barrett, AJ, et al., (eds.) “Thimet oligopeptidase.”Handbook of proteolytic enzymes(with cd-rom). [371], 1108-1111. 1998. San Diego, Academic Press.
Barrett, et al., “Thimet Oligopeptidase and Oligopeptidase M or Neurolysin [32],”Meth. Enzymol.248:529-556 (1995).
Barrett, et al., “Chicken liver Pz-peptidase, a thiol-dependent metallo-endopeptidase,”Biochem J271:701-706 (1990).
Baurain et al., “Amino Acid and Dipeptide Derivatives of Daunorubicin. 2. Cellular Pharmacology and Antitumor Activity on L1210 Leukemic Cells in Vitro and in Vivo,”J. Med. Chem23:1171-1174 (1980).
Baurain, et al, “Antitumor Activity of Daunorubicin Linked to Proteins: Lysosomal Hydrolysis and Antitumor Activity of Conjugates Prepared with Peptidic Spacer Arms,”Chemical Abstracts97:386 (1982).
Baurain, et al., “Antitumor Activity of Daunorubicin Linked to Proteins: Lysosomal Hydrolysis and Antitumor Activity of Conjugates Prepared with Peptidic Spacer Arms,” Curr. Chemother. Immunother., Proc. Int. Congr. Chemother., 12th(1982), vol. 2, 1430-32 (1982).
Baurain, et al., “Targeting of Daunorubicin by Covalent and Reversible Linkage to Carrier Proteins. Lysosomal Hydrolysis and Antitumoral Activity of Conjugates Prepared with Peptidic Spacers.”Drugs Exp. Clin.,vol. 9, pp. 303-311, 1983.
Bricout, Herve, et al., “Synthetic and Kinetic Aspects of Nickel-Catalysed Amination of Allylic Alcohol Derivatives,”Tetrahedron54:1073-1084 (1998).
Buchler, M, et al. “Proteinase yscD (oligopeptidase yscD). Structure, function and relationship of the yeast enzyme with mammalian thimet oligopeptidase (metalloendopeptidase, EP 24.15),”Eur.J.Biochem.219:627-639 (1994).
Camargo, AC, et al. “Structural requirements of bioactive peptides for interaction with endopeptidase 22.19,”Neuropeptides26:281-287 (1994).
Cardozo, C, et al. “Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropyl] -Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin converting enzyme,”Peptides14:1259-1262 (1993).
Casale, L, et al. “Quantitation of endopeptidase 24.11 and endopeptidase 24.15 in human blood leukocytes,”Enzyme Protein48:143-148 (1994).
Chaires, et al., “Self-Association of Daunomycin,”Biochemistry21:3927-32 (1982).
Chakravarty et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy. 1. Synthesis and Biological Activity of Peptidylacivicin and Peptidylphenylenediamine,”J. Med. Chem.26:633-638 (1983).
Chakravarty et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy. 2. Synthesis and Biological Activity of Peptidyl Derivatives of Doxorubicin,”J. Med. Chem.26:638-644 (1983).
Chen, et al. “Immunocalization of thimet oligopeptidase in chicken embryonic fibroblasts,”Exp. Cell Res216:80-85 (1995).
Chen, et al., “‘Analogous’ Organic Synthesis of Small-Compound Libraries: Validation of Combinatorial Chemistry in Small Molecule Synthesis,”J. Am. Chem. Soc.116:2661 (1994).
Confalonieri, et al., “The use of new laser particle sizer and shape analyser to detect and evaluate gelatinous microparticles suspended in reconstituted anthracycline infusion solutions,”J. Pharmaceut. Biomed. Anal.9:1-8 (1991).
Crack, et al., “The association of metalloendopeptidase EC 3.4.24.15 at the extracellular surafce of the AtT-20 cell plasma membrane,”Brain Res835:113-124 (1999).
Dando, et al., “Human thimet oligopeptidase,”Biochem J294:451-457 (1993).
De Marre, et al., “Evaluation of the hydrolytic and enzymatic stability of macromolecular Mitomycin C Derivatives,”J. Controlled Release31:89-97 (1994).
Delucia, et al., “Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal,”J. Vasc. Surg.18:49-60 (1993).
Dubois, et al. “Pharmacokinetics and Tissue Distribution of CPI-004, a New Prodrug of Doxorubicin, in Normal and Tumor-Bearing Mice.” Abstract #3329, American Association for Cancer Research, Scientific Proceedings, Apr. 1-5, 2000.
Eisenbrand et al., “An Approach Towards More Selective Anticancer Agents,” Synthesis, Synthesis pp. 1246-1258 (Oct. 1996).
Ekrami, et al., “Carbamylation decreases the cytotoxicity but not the drug-carrier properties of polylysines,”J. Drug Targ.2:469-475 (199

Affiliated with

Also associated with

Rating

Enzyme-cleavable prodrug compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enzyme-cleavable prodrug compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme-cleavable prodrug compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3986825